Clinical Trial Update: TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating TPIV100 in combination with sargramostim for HER2-positive breast cancer with residual disease after chemotherapy and surge…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Adenocarcinoma
• Breast Cancer

Drugs mentioned

• TPIV100 (TPIV100)
• sargramostim (sargramostim)

Snippet

Sponsor: Academic and Community Cancer Research United | Conditions: Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7 | Phase 2 | Status: UNKNOWN